Chong Kun Dang is lined up to copy 1 of the blockbuster drugs on this tracker, which earned $17.8B combined in 2025.
| Drug | Brand owner | Copy | US LOE | Chong Kun Dang's stage | 2025 brand sales |
|---|---|---|---|---|---|
| Dupixent | Sanofi / Regeneron | Biosimilar | 2031 | Phase 1 approved in EU and UK (Jan 2026) | $17.8B |
Each drug page lists sources for these entries. Brand sales show the size of the market, not Chong Kun Dang's share of it.